Department of Chemistry, Vanderbilt Institute of Nanoscale Science and Engineering, Vanderbilt Institute of Chemical Biology, Vanderbilt University, 7618 Stevenson Center, Nashville, TN37235, United States.
Department of Chemistry, Vanderbilt Institute of Nanoscale Science and Engineering, Vanderbilt Institute of Chemical Biology, Vanderbilt University, 7618 Stevenson Center, Nashville, TN37235, United States; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN37212, United States.
J Control Release. 2015 Dec 28;220(Pt B):751-7. doi: 10.1016/j.jconrel.2015.08.052. Epub 2015 Sep 3.
We report the synthesis and encapsulation of polyester nanosponge particles (NPs) co-loaded with tamoxifen (TAM) and quercetin (QT) to investigate the loading, release and in vitro metabolism of a dual drug formulation. The NPs are made in two variations, 4% and 8% crosslinking densities, to evaluate the effects on metabolism and release kinetics. The NP-4% formulation with a particle size of 89.3 ± 14.8 nm was found to have loading percentages of 6.91 ± 0.13% TAM and 7.72 ± 0.15% QT after targeting 10% (w/w) each. The NP-8% formulation with a particle size of 91.5 ± 9.8 nm was found to have loading percentages of 7.26 ± 0.10% TAM and 7.80 ± 0.12% QT. The stability of the formulation was established in simulated gastrointestinal fluids, and the metabolism of TAM was shown to be reduced 2-fold and 3-fold for NP-4%s and NP-8%s, respectively, while QT metabolism was reduced 3 and 4-fold. The implications for improved bioavailability of the NP formulations were supported by cytotoxicity results that showed a similar efficacy to free dual drug formulations and even enhanced anti-cancer effects in the recovery condition. This work demonstrates the suitability of the nanosponges not only as a dual release drug delivery system but also enabling a regulated metabolism through the capacity of a nanonetwork. The variation in crosslinking enables a dual release with tailored release kinetics and suggests improved bioavailability aided by a reduced metabolism.
我们报告了聚酯纳米海绵颗粒(NPs)的合成和封装,其共载有他莫昔芬(TAM)和槲皮素(QT),以研究双药物制剂的载药、释放和体外代谢情况。 NPs 有两种变化,交联密度为 4%和 8%,以评估对代谢和释放动力学的影响。NP-4%制剂的粒径为 89.3±14.8nm,载药量分别为 6.91±0.13%的 TAM 和 7.72±0.15%的 QT,靶向为 10%(w/w)。NP-8%制剂的粒径为 91.5±9.8nm,载药量分别为 7.26±0.10%的 TAM 和 7.80±0.12%的 QT。在模拟胃肠道液中建立了制剂的稳定性,结果表明,NP-4%和 NP-8%的 TAM 代谢分别减少了 2 倍和 3 倍,而 QT 代谢减少了 3 倍和 4 倍。NP 制剂生物利用度提高的意义得到了细胞毒性结果的支持,这些结果表明,NP 制剂与游离双药物制剂具有相似的疗效,甚至在恢复条件下增强了抗癌效果。这项工作不仅证明了纳米海绵作为一种双释放药物递送系统的适用性,还通过纳米网络的能力实现了调节代谢。交联密度的变化使双释放具有可定制的释放动力学,并通过降低代谢来提高生物利用度。